World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
86
Citations
34636
World Ranking
13938
National Ranking
738

Overview

Edwin DeJesus is affiliated with Hanover University of Applied Sciences and Arts in Germany. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with focused subfields in Infectious Diseases, Virology, Emergency Medicine, Epidemiology, and Immunology.

The scientist's work is predominantly centered on HIV/AIDS drug development and treatment, including HIV Research and Treatment, HIV/AIDS Research and Interventions, and HIV-related health complications and treatments. Other research topics include Hepatitis C virus research, Pneumocystis jirovecii pneumonia detection and treatment, and Pharmacological Effects and Toxicity Studies.

Notable recent publications by Edwin DeJesus include the following papers:

  • Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial (2020), published in The Lancet
  • Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection (2022), published in New England Journal of Medicine
  • Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection (2020), published in New England Journal of Medicine
  • Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial (2022), published in Nature Medicine
  • Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials (2020), published in The Lancet HIV

Frequent co-authors include:

  • Moti Ramgopal
  • Charlotte-Paige Rolle
  • Jean-Michel Molina
  • Sean E Collins
  • Diana M. Brainard

Edwin DeJesus has published repeatedly in the following venues:

  • Open Forum Infectious Diseases
  • The Lancet HIV
  • Nature Medicine
  • UNC Libraries
  • New England Journal of Medicine

Best Publications

  • Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

    Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka

  • Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

    Joel E. Gallant;Schlomo Staszewski;Anton L. Pozniak;Edwin DeJesus

  • The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

    Pereyra F;Jia X;McLaren Pj

  • Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

    Joel E. Gallant;Edwin Dejesus;José R. Arribas;Anton L. Pozniak

  • Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

    Eric Lawitz;Mark S Sulkowski;Reem Ghalib;Maribel Rodriguez-Torres

  • Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

    Roy M. Gulick;Jacob Lalezari;James Goodrich;Nathan Clumeck

  • Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

    Jeffrey L. Lennox;Edwin DeJesus;Adriano Lazzarin;Richard B. Pollard

  • Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

    Paul E Sax;David Wohl;Michael T Yin;Frank Post

  • Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine

    Scott M. Hammer;Magdalena E. Sobieszczyk;Holly Janes;Shelly T. Karuna

  • Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

    Paul E. Sax;Edwin DeJesus;Anthony Mills;Andrew Zolopa

  • Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

    Roberto Ortiz;Edwin DeJesus;Homayoon Khanlou;Evgeniy Voronin

  • The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

    Joseph Eron;Patrick Yeni;Joseph Gathe;Vicente Estrada

  • Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

    Edwin DeJesus;Jürgen K. Rockstroh;Keith Henry;Jean Michel Molina

  • Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

    Eric Lawitz;Jay P Lalezari;Tarek Hassanein;Kris V Kowdley

  • Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

    Antonella Castagna;Franco Maggiolo;Giovanni Penco;David Wright

  • Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

    Joseph J Eron;Benjamin Young;David A Cooper;Michael Youle

  • Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients

    Edwin Dejesus;Daniel Berger;Martin Markowitz;Calvin Cohen

  • Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

    Mark Sulkowski;Christophe Hezode;Jan Gerstoft;John M Vierling

  • Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.

    Ann R Falsey;Magdalena E Sobieszczyk;Ian Hirsch;Stephanie Sproule

  • Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.

    Peter J. Ruane;Edwin DeJesus;Daniel Berger;Martin Markowitz

Frequent Co-Authors

Paul E. Sax
Paul E. Sax Brigham and Women's Hospital
Peter Ruane
Peter Ruane Ruane Medical
Jean-Michel Molina
Jean-Michel Molina Université Paris Cité
Joel E. Gallant
Joel E. Gallant Johns Hopkins University School of Medicine
Jose R. Arribas
Jose R. Arribas Hospital Universitario La Paz
Chloe Orkin
Chloe Orkin Queen Mary University of London
Anton Pozniak
Anton Pozniak London School of Hygiene & Tropical Medicine
Adriano Lazzarin
Adriano Lazzarin Vita-Salute San Raffaele University
Anthony Rodgers
Anthony Rodgers University of New South Wales
Graeme Moyle
Graeme Moyle Chelsea and Westminster Hospital NHS Foundation Trust

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine but want alternative or supplementary pathways, a variety of online healthcare degrees can open exciting opportunities. Many students choose an online pharmacist degree to become practicing pharmacists, combining healthcare knowledge with patient interaction. For those interested in healthcare administration and technology, an online bachelor's in health information management prepares you to manage patient records, data security, and healthcare IT systems.

Medical billing and coding specialists streamline healthcare finances and insurance procedures. A low cost medical coding and billing online program offers a practical, in-demand skillset you can achieve quickly and affordably. Aspiring advanced practice nurses can opt for the most affordable nurse practitioner programs, allowing for clinical careers with autonomy and the ability to diagnose and treat patients.

Each of these online degrees provides flexible entry into the healthcare field. They are ideal for students seeking alternative career pathways, more affordable options, or the chance to specialize outside traditional medical school routes.

Best Scientists Citing Edwin DeJesus

Trending Scientists